Im­muno­Gen’s ovar­i­an can­cer treat­ment helps pa­tients live longer than chemo in con­fir­ma­to­ry tri­al

In No­vem­ber, the FDA grant­ed ac­cel­er­at­ed ap­proval to Im­muno­Gen’s drug Ela­here for ad­vanced ovar­i­an can­cer — the first new treat­ment for the dis­ease in at least sev­en years.

On Wednes­day morn­ing, the Mass­a­chu­setts biotech an­nounced that in its con­fir­ma­to­ry tri­al, called MI­RA­SOL, Ela­here re­duced the risk of death by 33% com­pared to chemother­a­py in pa­tients who’ve re­ceived at least one pre­vi­ous treat­ment — though near­ly half of pa­tients in the tri­al had tried three pre­vi­ous ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER